Limits...
CD163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients.

Yang L, Wang F, Wang L, Huang L, Wang J, Zhang B, Zhang Y - Oncotarget (2015)

Bottom Line: Here, we found that the percentage of CD163+ TAMs in MPE was significantly higher than that in non-malignant pleural effusion (P<0.001).These findings highlight that accumulation of CD163+ TAMs in MPE caused by lung cancer is closely correlated with poor prognosis.CD163+ TAMs are associated with therapeutic effect in MPE.

View Article: PubMed Central - PubMed

Affiliation: Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.

ABSTRACT
CD163+ tumor-associated macrophages (TAMs) play an important role in the progression of cancer. However, the significance of CD163+ TAMs in malignant pleural effusion (MPE) is still unclear. The aim of this study is to evaluate the prognostic value of CD163+ TAMs in MPE, and the regulatory effect of an immune adjuvant (pseudomonas aeruginosa - mannose-sensitive hemagglutinin, PA-MSHA, which is used for MPE treatment in clinic) on CD163+ TAMs in MPE. Here, we found that the percentage of CD163+ TAMs in MPE was significantly higher than that in non-malignant pleural effusion (P<0.001). More importantly, CD163+ TAMs in MPE patients were an independent prognostic factor for progression-free survival. M2-related cytokines were highly expressed in MPE-derived CD163+ TAMs than in MPE-derived CD163- macrophages (P<0.05). CD163+ TAMs frequency in MPE patients was obviously reduced after PA-MSHA treatment in clinic (P<0.05). After treatment with PA-MSHA, M2 macrophages were re-educated to M1 macrophages in vitro. TLR4 blocking antibody inhibited M2 macrophages polarization to M1 macrophages induced by PA-MSHA. These findings highlight that accumulation of CD163+ TAMs in MPE caused by lung cancer is closely correlated with poor prognosis. CD163+ TAMs are associated with therapeutic effect in MPE. PA-MSHA re-educates CD163+ TAMs to M1 macrophages through TLR4-mediated pathway in MPE.

No MeSH data available.


Related in: MedlinePlus

Effect of PA-MSHA on NK cytotoxicity impaired by CD163+ TAMsNK cytotoxicity assay was analyzed by flow cytometry. One representative analysis is shown. The results of NK cytotoxicity assay are presented as histogram. Control = NK cells + K562 cells; Untreated = macrophages + NK cells + K562 cells; Treated = macrophages + NK cells + K562 cells + PA-MSHA. * = P<0.05, ns = non-significance.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496378&req=5

Figure 5: Effect of PA-MSHA on NK cytotoxicity impaired by CD163+ TAMsNK cytotoxicity assay was analyzed by flow cytometry. One representative analysis is shown. The results of NK cytotoxicity assay are presented as histogram. Control = NK cells + K562 cells; Untreated = macrophages + NK cells + K562 cells; Treated = macrophages + NK cells + K562 cells + PA-MSHA. * = P<0.05, ns = non-significance.

Mentions: Then we investigated CD163+ TAMs affected NK cytotoxicity. With co-incubation of CD163+ TAMs, NK cell killing was significantly lower than control (P=0.0291, Figure 5), which showed that CD163+ TAMs inhibited NK cells killing. After that, the effect of CD163+ TAMs on NK cytotoxicity affected by PA-MSHA was performed. After treatment with PA-MSHA, NK cytotoxicity was obviously reversed compared to untreated group (P=0.0339, Figure 5). Overall, PA-MSHA restores the cytotoxicity of NK cells impaired by CD163+ TAMs.


CD163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients.

Yang L, Wang F, Wang L, Huang L, Wang J, Zhang B, Zhang Y - Oncotarget (2015)

Effect of PA-MSHA on NK cytotoxicity impaired by CD163+ TAMsNK cytotoxicity assay was analyzed by flow cytometry. One representative analysis is shown. The results of NK cytotoxicity assay are presented as histogram. Control = NK cells + K562 cells; Untreated = macrophages + NK cells + K562 cells; Treated = macrophages + NK cells + K562 cells + PA-MSHA. * = P<0.05, ns = non-significance.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496378&req=5

Figure 5: Effect of PA-MSHA on NK cytotoxicity impaired by CD163+ TAMsNK cytotoxicity assay was analyzed by flow cytometry. One representative analysis is shown. The results of NK cytotoxicity assay are presented as histogram. Control = NK cells + K562 cells; Untreated = macrophages + NK cells + K562 cells; Treated = macrophages + NK cells + K562 cells + PA-MSHA. * = P<0.05, ns = non-significance.
Mentions: Then we investigated CD163+ TAMs affected NK cytotoxicity. With co-incubation of CD163+ TAMs, NK cell killing was significantly lower than control (P=0.0291, Figure 5), which showed that CD163+ TAMs inhibited NK cells killing. After that, the effect of CD163+ TAMs on NK cytotoxicity affected by PA-MSHA was performed. After treatment with PA-MSHA, NK cytotoxicity was obviously reversed compared to untreated group (P=0.0339, Figure 5). Overall, PA-MSHA restores the cytotoxicity of NK cells impaired by CD163+ TAMs.

Bottom Line: Here, we found that the percentage of CD163+ TAMs in MPE was significantly higher than that in non-malignant pleural effusion (P<0.001).These findings highlight that accumulation of CD163+ TAMs in MPE caused by lung cancer is closely correlated with poor prognosis.CD163+ TAMs are associated with therapeutic effect in MPE.

View Article: PubMed Central - PubMed

Affiliation: Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.

ABSTRACT
CD163+ tumor-associated macrophages (TAMs) play an important role in the progression of cancer. However, the significance of CD163+ TAMs in malignant pleural effusion (MPE) is still unclear. The aim of this study is to evaluate the prognostic value of CD163+ TAMs in MPE, and the regulatory effect of an immune adjuvant (pseudomonas aeruginosa - mannose-sensitive hemagglutinin, PA-MSHA, which is used for MPE treatment in clinic) on CD163+ TAMs in MPE. Here, we found that the percentage of CD163+ TAMs in MPE was significantly higher than that in non-malignant pleural effusion (P<0.001). More importantly, CD163+ TAMs in MPE patients were an independent prognostic factor for progression-free survival. M2-related cytokines were highly expressed in MPE-derived CD163+ TAMs than in MPE-derived CD163- macrophages (P<0.05). CD163+ TAMs frequency in MPE patients was obviously reduced after PA-MSHA treatment in clinic (P<0.05). After treatment with PA-MSHA, M2 macrophages were re-educated to M1 macrophages in vitro. TLR4 blocking antibody inhibited M2 macrophages polarization to M1 macrophages induced by PA-MSHA. These findings highlight that accumulation of CD163+ TAMs in MPE caused by lung cancer is closely correlated with poor prognosis. CD163+ TAMs are associated with therapeutic effect in MPE. PA-MSHA re-educates CD163+ TAMs to M1 macrophages through TLR4-mediated pathway in MPE.

No MeSH data available.


Related in: MedlinePlus